相关实验视频

Updated: Jul 25, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.3K

在关键的亚特兰蒂斯研究中,基于模型的单剂lurbinectedin的对比比较

Salvador Fudio1, Laura Pérez-Ramos1, Eduardo Asín-Prieto1

  • 1Clinical Pharmacology Department, PharmaMar, S.A., Madrid, Spain.

Frontiers in oncology
|July 3, 2023
PubMed
概括

卢比尼克丁单一疗法在治疗复发性小细胞肺癌 (SCLC) 中显示出优越性. 这项分析预测,在ATLANTIS试验中, Lurbinectedin在3.2 mg/m2的剂量提供了比组合疗法更好的结果.

关键词:
亚特兰蒂斯是亚特兰蒂斯的一座城市.在SCLC中,SCLC是最重要的.暴露-反应的情况.在Lurbine中进行了实验.建模 建模模型 建模模型模拟模拟是指一个模拟模拟.

更多相关视频

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.3K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

180

相关概念视频

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).